Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

NZS Capital - Growth 2023 Q4 Investor Letter | Buyside Digest

Back to Fund Profile (NZS Capital - Growth)

Primary Source Intelligence • Q4 2023 Letter Analysis

NZS Capital - Growth Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, NZS Capital - Growth. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+16.01%

YTD+34.44%

Annualized+15.36%

Positioning StanceConstructive

Market CapLarge Cap

GeographyUS, Global

Digest Analysis

Quick Take

"NZS delivered strong Q4 performance through disciplined stock selection, avoiding Magnificent Seven momentum while maintaining innovation focus. Portfolio balances resilient holdings like Trane Technologies with optional positions, emphasizing companies creating win-win outcomes."

Executive Summary

NZS Capital's Growth Strategy delivered strong Q4 2023 performance, up 16% net versus 11% for the benchmark, benefiting from rate cut expectations and broader market rally. The portfolio maintains high exposure to information technology while increasingly finding opportunities across sectors, reflecting focus on innovation beyond mega platforms. Key contributors included Microsoft, ASML, and Workday, while the manager sold positions like Amazon and Nextera based on fundamental concerns. The strategy promoted Trane Technologies to its resilience sleeve, highlighting the company's leadership in HVAC and alignment with decarbonization trends. Looking ahead, the manager expects a broader-based market in 2024 as Magnificent Seven momentum fades, with stock selection becoming more important than sector allocation. While maintaining conviction in AI's transformational impact, particularly in healthcare and scientific research, the portfolio avoids momentum trades in favor of companies with favorable risk-adjusted return profiles. The balanced approach positions the strategy to benefit from stabilizing end markets and continued innovation-driven growth.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

Manager demonstrates moderate-high conviction through specific position sizing decisions, named holdings with clear rationales, and willingness to sell underperformers like Amazon and Nextera. However, diversified 59-name portfolio and acknowledgment of wide outcome ranges prevents higher scoring.

Growth Outlook

50%

BearishBullish

Neutral (50%)

Manager expresses constructive optimism about 2024 with expectations of a broader market and diminishing impact of rates, but balances this with concerns about Magnificent Seven valuations and acknowledges ongoing economic uncertainties.

Risk Appetite

25%

DefensiveAggressive

Defensive (25%)

Portfolio maintains selective risk appetite with underweights to momentum names like Nvidia and Tesla, while adding to healthcare and promoting Trane to resilience sleeve, indicating measured rather than aggressive positioning.

Capital Deployment

45%

De-riskingDeploying

Net Neutral (45%)

Net neutral activity with rotation from Amazon and Autodesk into healthcare names and ANSYS. Added new position in Shockwave Medical but overall represents capital rotation rather than net deployment, with cash remaining low at 0.6%.

Forward Guidance

25%

CautiousExpansionary

Cautious (25%)

Manager plans selective deployment in healthcare and other sectors while maintaining disciplined approach, avoiding momentum trades and focusing on fundamental stock selection rather than aggressive capital deployment.

Language Signal

25%

BearishBullish

Bearish (25%)

Language balances opportunity recognition (broader market, AI transformation, stabilizing cycles) with risk awareness (Magnificent Seven concerns, valuation risks, range of outcomes), resulting in measured optimistic tone.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

Manager identifies specific risks around Magnificent Seven valuations and acknowledges wide range of outcomes for momentum stocks, but frames most risks as manageable through stock selection rather than systemic threats.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Manager sees selective opportunities across sectors beyond technology, adding healthcare names and finding companies aligned with decarbonization trends, though emphasizes need for selectivity and fundamental analysis over broad deployment.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

Strategy emphasizes long-term theses and fundamental progress over quarters, with resilient holdings designed for multi-year holding periods and focus on sustainable competitive advantages rather than near-term catalysts.